Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Vermeire

Showing results (91-100 of 95) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 95 results.
Journal of Crohn'S & Colitis|February 6, 2018
Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's DiseaseDaniël R Hoekman, Judith A Stibbe, Filip J Baert, et al.
The European Respiratory Journal|January 3, 2006
Epidemiology and costs of chronic obstructive pulmonary diseaseK R Chapman, D M Mannino, J B Soriano, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonistA A H P Megens, D Ashton, J C A Vermeire, et al.
The European Respiratory Journal|April 6, 2006
Increasing COPD awarenessJ Zielinski, M Bednarek, D Górecka, et al.
Inflammatory Bowel Diseases|July 26, 2013
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapyMartine De Vos, Edouard J Louis, Jørgen Jahnsen, et al.
Pageof 10

Showing results (91-100 of 95) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 95 results.
Journal of Crohn'S & Colitis|February 6, 2018
Long-term Outcome of Early Combined Immunosuppression Versus Conventional Management in Newly Diagnosed Crohn's DiseaseDaniël R Hoekman, Judith A Stibbe, Filip J Baert, et al.
The European Respiratory Journal|January 3, 2006
Epidemiology and costs of chronic obstructive pulmonary diseaseK R Chapman, D M Mannino, J B Soriano, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 20, 2002
Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonistA A H P Megens, D Ashton, J C A Vermeire, et al.
The European Respiratory Journal|April 6, 2006
Increasing COPD awarenessJ Zielinski, M Bednarek, D Górecka, et al.
Inflammatory Bowel Diseases|July 26, 2013
Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapyMartine De Vos, Edouard J Louis, Jørgen Jahnsen, et al.
Pageof 10